カテゴリー： 世界

局所進行膵がんの世界市場-2024年～2031年

【英語タイトル】Locally Advanced Pancreatic Cancer Market Size, Share, Industry, Forecast and Outlook (2024-2031)

DataM Intelligenceが出版した調査資料（PH6764）・商品コード：PH6764
・発行会社（調査会社）：DataM Intelligence
・発行日：2024年12月
・ページ数：180
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,350 ⇒換算￥652,500見積依頼/購入/質問フォーム
Enterprise User License（閲覧人数無制限）USD7,850 ⇒換算￥1,177,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Global Locally Advanced Pancreatic Cancer market reached USD 0.9 billion in 2022 and is expected to reach USD 2.0 billion by 2030, growing with a CAGR of 11.1% during the forecast period 2024-2031.

Pancreatic cancer is generally represented by its aggressive tumor expansion and dismal prognosis. When patients demonstrate pancreatic cancer, less than 10% have tumors that are potentially treatable with resection, and roughly one-third have metastatic conditions. The rest (more than one-half of all patients with pancreatic cancer) have a condition that is believed to be locally progressive and unresectable pancreatic cancer (LAPC) as an outcome of local invasion of adjacent structures.

Pancreatic adenocarcinoma is among the most aggressive therapy of tumor and is expected to emerge as the second top reason for cancer-related mortalities in Europe and the United States by 2030. The projection has barely enhanced over the last twenty years and stays down, with a general 5-year survival rate of roughly 8% individuals affected with the condition. Pancreatic cancer is generally diagnosed in later stages, and unintended weight loss, continued loss of hunger, etc. are a few manifestations noticed in patients. The treatment for locally advanced pancreatic cancer includes surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy selected depending on the condition.

The growing cases of pancreatic cancer, increasing initiatives to spread awareness, and support efforts among other factors are expected to boost the global locally advanced pancreatic cancer market growth during the forecast period. Further, the increasing research activities owing to the rising fundings and investments are expected to boost the global Locally Advanced Pancreatic Cancer market growth in the forecast period.

❖ レポートの目次 ❖

Market Dynamics

Growing Cases of Locally Advanced Pancreatic Cancer Drive the Market Growth

The growing cases of locally advanced pancreatic cancer globally are expected to boost the global market growth during the forecast period. For instance, approximately 30% of individuals with pancreatic cancer are with locally advanced conditions.  Also, according to an article published by NCBI, about 21,859 new patients of pancreatic cancer were registered in Germany in 2021. The growth in nicotine smoking and the increase in tobacco consumption are among the factors leading to the boost in the number of patients with this cancer.

Moreover, according to the forecasts made in Advances in Pancreatic Ductal Adenocarcinoma Diagnosis and Treatment article, the number of individuals with pancreatic cancer is expected to grow. By 2025, it is assessed that the number of fresh cases will grow by 9829, and by 2040 by 37,824. The pancreatic cancer-caused mortality is expected to rise to 141,653 deaths in 2025, and to 169,389 in 2040 around 37,255 more deaths compared to 2020. Again, according to WCRF International, pancreatic cancer is the 12th most typical cancer globally. It is the 12th most typical cancer in males and the 11th most expected cancer in females. There were over 495,000 fresh cases of pancreatic cancer in 2020.

Increasing Research Developments

The increasing research development for the treatment for pancreatic cancer treatment are expected to boost the global locally advanced pancreatic cancer market growth in the forecast period. For instance, The January 2022, Multitargeted T-cell therapy was awarded orphan drug status by the U.S. Food and Drug Administration (FDA) for the therapy of pancreatic cancer. When utilized in combination with chemotherapy, this therapy has the prospect of producing long-lasting results in individuals with progressive or metastatic pancreatic cancer.

Further, in January 2022, Novartis AG obtained an Orphan Drug Designation (ODD) for NIS793 from the U.S. FDA. It integrates with additional chemotherapy medicines for the treatment of pancreatic cancer and other tumors. Similarly, in June 2023, RenovoRx, Inc., a clinical-stage biopharmaceutical corporation designing targeted blend therapies, delivered new positive data on progression-free survival (PFS) from the pivotal Phase III open-label TIGeR-PaC investigation of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer (LAPC).

High Therapy Costs

  • High therapy costs are significantly hampering the growth of the locally advanced pancreatic cancer market by limiting patient access, straining healthcare budgets and slowing adoption of innovative therapies.
  • The cost of advanced pancreatic cancer treatments, such as FOLFIRINOX, targeted therapies (e.g., PARP inhibitors like Lynparza), or immunotherapies, often exceeds the affordability of many patients, particularly in low- and middle-income countries.
  • For instance, according to the Study Conducted by the National Institute of Health, the average five-year cost of treatment was USD 101,518 for FOLFIRINOX, placing a heavy financial burden on patients without robust insurance coverage.
  • High therapy costs increase the financial burden on insurance companies and public health programs. In countries with universal healthcare, the high cost of pancreatic cancer treatments leads to stricter reimbursement criteria, delaying or denying access for patients.

Therapy Side-effects

The side effects of chemotherapy rely on which medications are administered. Also, not all individuals have identical side effects even if the same medication is given. Overall the side effects include poor hunger, nauseousness, vomiting, diarrhea, gastrointestinal issues, hives, mouth sores, hair loss, and a deficiency of energy. Individuals accepting chemotherapy are even additional prone to hold low levels of WBCs, RBCs, and Thrombocytes, which puts the individuals at an increased threat of anemia, infections, bruising, and bleeding.

A few drugs utilized in pancreatic cancer are even connected with typical side effects. For instance, capecitabine can provoke redness and discomfort on the palms of the hands and the soles of the feet. This state is called hand-foot syndrome. Oxaliplatin can induce cold sensitivity numbness and tingling in the fingers and toes, anointed peripheral neuropathy. Peripheral neuropathy is an unwanted effect of nab-paclitaxel as well.

Market Segment Analysis

The global locally advanced pancreatic cancer market is segmented based on therapy, route of administration, end-user and region.

Chemotherapy is Expected to Dominate Market

Chemotherapy is estimated to hold a major share of the global locally advanced pancreatic cancer market which is around 38.6% of the market share as the initial treatment for locally advanced pancreatic cancer is systemic chemotherapy. The introduction of FOLFIRINOX chemotherapy and gemcitabine-nab-paclitaxel (gem-nab) holds significant importance for the management and results of patients with locally advanced pancreatic cancer.

For instance, according to a clinical investigation post 4–6 months of induction chemotherapy, the bulk of individuals showed steady condition or even tumor-regression. Around 12 to 35% of individuals successfully downstaged to resectable condition. Further, according to the first interim analysis of the phase III TIGeR-PaC trial presented at ESMO GI 2023, in individuals with locally advanced pancreatic cancer, therapy with intra-arterial gemcitabine directs to better survival and safety results than with the standard-of-care therapy with intravenous gemcitabine/nab-paclitaxel.

Market Geographical Share

Increasing Number of Pancreas Cancer Cases in North America

North America is estimated to hold around 38.2% of the total market share in 2023. Owing to the increasing number of pancreas cancer cases, government funding, and awareness initiatives are boosting the regional market growth during the forecast period. For instance, the American Cancer Society’s Cancer Facts & Figures 2023, indicates that an assessed over 64,050 Americans to be detected with pancreatic cancer in 2023, more individuals than ever in history. Also, approximately 50,550 Americans are expected to die from the condition in 2023.

Further, pancreatic cancer is presently the 10th most highly detected cancer in the U.S., it remains the third-leading reason for cancer-related deaths. Pancreatic cancer is on the path to evolve as the second-highest reason for cancer-related mortalities before 2030. Similarly, according to the CDC Annual Report to the Nation 2022, in males, the most significant incidence rate boost was witnessed in pancreatic cancer, which grew by 1.1% per year, and the abruptest incidence rate reduction was witnessed in lung cancer, which fell by 2.6% per year. Furthermore, in August 2022, PanTher Therapeutics, a clinical-stage oncology corporation designing next-generation targeted treatments for solid tumors, acquired $14.2 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT).

The grant is intended to be employed to extend clinical development via Phase 2 of PanTher’s principal investigational treatment, PTM-101, a minimally invasive, implantable therapy for non-metastatic pancreatic cancer that delivers a direct, sustained discharge of a known therapeutic drug at the tumor location. Additionally, in June 2023, a $3.3 million grant from the National Cancer Institute by the U.S. Department of Health and Human Services was awarded to UTHealth Houston to investigate a combination strategy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with chemotherapy for pancreatic cancer.

Russia-Ukraine War Impact

The Russia-Ukraine conflict has negatively impacted the global locally advanced pancreatic cancer market growth. Since the invasion of Ukraine in February 2022, the execution of clinical trials has become quite difficult owing to the deterioration of healthcare establishments and patient displacement. For instance, according to an illustrative investigation, and narrative examination was conducted utilizing data from cancer clinical trials with sites in Russia or Ukraine employing the ‘clinical trials.gov’ online database between February 2022 and May 2022.

There were 508 clinical trials concerning locations in Ukraine or Russia. A majority of these were global investigations accounting for 93% of total studies. The most of investigations were phase 3 accounting for 68% of the total and these even held the most extensive specimen sizes ranging from 12–5637. This has created disruption in the treatment research activities hampering the growth in the forthcoming years.

COVID-19 Impact Analysis

The pandemic had an intermediate impact on the global market as at the beginning many procedures and visits were postponed or canceled which negatively impacted the market. However, according to the Pancreatic Cancer Organization UK, several individuals with pancreatic cancer are at elevated threat of becoming extremely ill if exposed to coronavirus infection. Individuals with people with cancer who are having chemotherapy have compromised immunity since the chemotherapy weakens the immune system, making it harder for the body to resist an infection.

Also, individuals who have had their spleen extracted, as some surgery for pancreatic cancer concerns removing the spleen are at increased threat for infection since the spleen is an important part of the immune system. Similarly, the individuals undergoing radiotherapy or immunotherapy may also be at elevated risk. This has caused immediate actions to restore the pancreatic cancer healthcare assistance programs.

By Therapy

  • Chemotherapy
    • Gemcitabine
    • 5-fluorouracil (5-FU)
    • Oxaliplatin
    • Albumin-bound paclitaxel (Abraxane)
    • Capecitabine (an oral 5-FU drug)
    • Cisplatin
    • Irinotecan
    • Others
  • Immunotherapy
    • Dostarlimab
    • Pembrolizumab
  • Targeted Therapy
    • Larotrectinib
    • Entrectinib
  • Radiation Therapy
  • Surgery
    • Whipple Procedure
    • Total Pancreatectomy
    • Distal Pancreatectomy

By Route of Administration

  • Oral
  • Injectables
  • Others

By End-User

  • Hospital
  • Specialty Clinics
  • Research Institutions
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In January 2022, Novartis AG obtained an Orphan Drug Designation (ODD) for NIS793 from the U.S. FDA. It integrates with other chemotherapy medications for the treatment of pancreatic cancer and other tumors.
  • In January 2022, AstraZeneca teamed with Scorpion Therapeutics to discover, design, and market precision therapies against formerly hard-to-target cancer proteins.
  • In September 2021 F. Hoffmann-La Roche Ltd collaborated with NovoCure to design Tumor Treating Fields (TTFields) in a mixture with anti-PD-L1 therapy, atezolizumab, for individuals detected with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Market Major Players

The major global players in the market include Theratechnologies Inc., Amryt Pharmaceuticals, Inc., Fawn Incorporation, Abbott Healthcare Solutions, Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer Inc., AstraZeneca, Novartis Pharmaceuticals Corporation, AbbVie, Galderma Laboratories, L.P. and GlaxoSmithKline among others.

 

  1. Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report

  2. Definition and Overview

  3. Executive Summary

    1. Snippet by Therapy
    2. Snippet by Route of Administration
    3. Snippet by End-User
    4. Snippet by Region

  4. Dynamics

    1. Impacting Factors
      1. Drivers
        1. Growing Cases of Locally Advanced Pancreatic Cancer
        2. Increasing Research Developments
      2. Restraints
        1. High Therapy Costs
        2. Therapy Side-effects
      3. Opportunity
      4. Impact Analysis

  5. Industry Analysis

    1. Porter’s Five Force Analysis
    2. Supply Chain Analysis
    3. Pricing Analysis
    4. Pipeline Analysis
    5. Regulatory Analysis
    6. Patent Analysis
    7. End-User Trend
    8. SWOT Analysis
    9. DMI Opinion
    10. Russia-Ukraine War Impact

  6. COVID-19 Analysis

    1. Analysis of COVID-19
      1. Scenario Before COVID
      2. Scenario During COVID
      3. Scenario Post COVID
    2. Pricing Dynamics Amid COVID-19
    3. Demand-Supply Spectrum
    4. Government Initiatives Related to the Market During Pandemic
    5. Manufacturers Strategic Initiatives
    6. Conclusion

  7. By Therapy

    1. Introduction
      1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
      2. Market Attractiveness Index, By Therapy
    2. Chemotherapy*
      1. Introduction
      2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      3. Gemcitabine
      4. 5-fluorouracil (5-FU)
      5. Oxaliplatin
      6. Albumin-bound paclitaxel (Abraxane)
      7. Capecitabine (an oral 5-FU drug)
      8. Cisplatin
      9. Irinotecan
      10. Others
    3. Immunotherapy
      1. Dostarlimab
      2. Pembrolizumab
    4. Targeted Therapy
      1. Larotrectinib
      2. Entrectinib
    5. Radiation Therapy
    6. Surgery
      1. Whipple Procedure
      2. Total Pancreatectomy
      3. Distal Pancreatectomy

  8. By Route of Administration

    1. Introduction
      1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
      2. Market Attractiveness Index, By Route of Administration
    2. Oral*
      1. Introduction
      2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    3. Injectables
    4. Others

  9. By End-User

    1. Introduction
      1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
      2. Market Attractiveness Index, By End-User
    2. Hospital*
      1. Introduction
      2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    3. Specialty Clinics
    4. Research Institutions
    5. Others

  10. By Region

    1. Introduction
      1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
      5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
      5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. UK
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
      5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia-Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
      5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia-Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
      5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

  11. Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis

  12. Company Profiles

    1. GSK*
      1. Company Overview
      2. Product Portfolio and Description
      3. Financial Overview
      4. Key Developments
    2. Merck & Co., Inc.
    3. Bristol-Myers Squibb Company
    4. Getwell
    5. Ipsen Biopharmaceuticals, Inc.
    6. Novartis Pharmaceuticals Corporation
    7. Pfizer
    8. Bayer HealthCare Pharmaceuticals, Inc.
    9. Genentech USA, Inc.
    10. AstraZeneca (*LIST NOT EXHAUSTIVE) 

  13. Appendix

    1. About Us and Services
    2. Contact Us

List of Tables

Table 1 Global Locally Advanced Pancreatic Cancer Market Value, By Therapy, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Locally Advanced Pancreatic Cancer Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Locally Advanced Pancreatic Cancer Market Value, By End-User, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Locally Advanced Pancreatic Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Locally Advanced Pancreatic Cancer Market Value, By Therapy, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Locally Advanced Pancreatic Cancer Market Value, By Therapy, 2021-2030 (US$ Billion)

Table 7 Global Locally Advanced Pancreatic Cancer Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Locally Advanced Pancreatic Cancer Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 9 Global Locally Advanced Pancreatic Cancer Market Value, By End-User, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Locally Advanced Pancreatic Cancer Market Value, By End-User, 2021-2030 (US$ Billion)

Table 11 Global Locally Advanced Pancreatic Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Locally Advanced Pancreatic Cancer Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Locally Advanced Pancreatic Cancer Market Value, By Therapy, 2021-2030 (US$ Billion)

Table 14 North America Locally Advanced Pancreatic Cancer Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 15 North America Locally Advanced Pancreatic Cancer Market Value, By End-User, 2021-2030 (US$ Billion)

Table 16 North America Locally Advanced Pancreatic Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Locally Advanced Pancreatic Cancer Market Value, By Therapy, 2021-2030 (US$ Billion)

Table 18 South America Locally Advanced Pancreatic Cancer Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 19 South America Locally Advanced Pancreatic Cancer Market Value, By End-User, 2021-2030 (US$ Billion)

Table 20 South America Locally Advanced Pancreatic Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Locally Advanced Pancreatic Cancer Market Value, By Therapy, 2021-2030 (US$ Billion)

Table 22 Europe Locally Advanced Pancreatic Cancer Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 23 Europe Locally Advanced Pancreatic Cancer Market Value, By End-User, 2021-2030 (US$ Billion)

Table 24 Europe Locally Advanced Pancreatic Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Locally Advanced Pancreatic Cancer Market Value, By Therapy, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Locally Advanced Pancreatic Cancer Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Locally Advanced Pancreatic Cancer Market Value, By End-User, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Locally Advanced Pancreatic Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East & Africa Locally Advanced Pancreatic Cancer Market Value, By Therapy, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Locally Advanced Pancreatic Cancer Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Locally Advanced Pancreatic Cancer Market Value, By End-User, 2021-2030 (US$ Billion)

Table 32 GSK: Overview

Table 33 GSK: Product Portfolio

Table 34 GSK: Key Developments

Table 35 Merck & Co., Inc.: Overview

Table 36 Merck & Co., Inc.: Product Portfolio

Table 37 Merck & Co., Inc.: Key Developments

Table 38 Bristol-Myers Squibb Company: Overview

Table 39 Bristol-Myers Squibb Company: Product Portfolio

Table 40 Bristol-Myers Squibb Company: Key Developments

Table 41 Getwell: Overview

Table 42 Getwell: Product Portfolio

Table 43 Getwell: Key Developments

Table 44 Ipsen Biopharmaceuticals, Inc.: Overview

Table 45 Ipsen Biopharmaceuticals, Inc.: Product Portfolio

Table 46 Ipsen Biopharmaceuticals, Inc.: Key Developments

Table 47 Novartis Pharmaceuticals Corporation: Overview

Table 48 Novartis Pharmaceuticals Corporation: Product Portfolio

Table 49 Novartis Pharmaceuticals Corporation: Key Developments

Table 50 Pfizer: Overview

Table 51 Pfizer: Product Portfolio

Table 52 Pfizer: Key Developments

Table 53 Bayer HealthCare Pharmaceuticals, Inc.: Overview

Table 54 Bayer HealthCare Pharmaceuticals, Inc.: Product Portfolio

Table 55 Bayer HealthCare Pharmaceuticals, Inc.: Key Developments

Table 56 Genentech USA, Inc.: Overview

Table 57 Genentech USA, Inc.: Product Portfolio

Table 58 Genentech USA, Inc.: Key Developments

Table 59 AstraZeneca: Overview

Table 60 AstraZeneca: Product Portfolio

Table 61 AstraZeneca: Key Developments

 

List of Figures

Figure 1 Global Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Locally Advanced Pancreatic Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 3 Global Locally Advanced Pancreatic Cancer Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Locally Advanced Pancreatic Cancer Market Share, By End-User, 2022 & 2030 (%)

Figure 5 Global Locally Advanced Pancreatic Cancer Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Locally Advanced Pancreatic Cancer Market Y-o-Y Growth, By Therapy, 2022-2030 (%)

Figure 7 Chemotherapy Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 8 Immunotherapy Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 9 Targeted Therapy Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 10 Radiation Therapy Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 11 Surgery Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 12 Global Locally Advanced Pancreatic Cancer Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 13 Oral Route of Administration in Global Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 14 Injectables Route of Administration in Global Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 15 Others Route of Administration in Global Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 16 Global Locally Advanced Pancreatic Cancer Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 17 Hospital End-User in Global Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 18 Specialty Clinics End-User in Global Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 19 Research Institutions End-User in Global Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 20 Others End-User in Global Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 21 Global Locally Advanced Pancreatic Cancer Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 23 Asia-Pacific Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 24 Europe Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 25 South America Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 26 Middle East and Africa Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 27 North America Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 28 North America Locally Advanced Pancreatic Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 29 North America Locally Advanced Pancreatic Cancer Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 30 North America Locally Advanced Pancreatic Cancer Market Share, By End-User, 2022 & 2030 (%)

Figure 31 North America Locally Advanced Pancreatic Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 33 South America Locally Advanced Pancreatic Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 34 South America Locally Advanced Pancreatic Cancer Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 35 South America Locally Advanced Pancreatic Cancer Market Share, By End-User, 2022 & 2030 (%)

Figure 36 South America Locally Advanced Pancreatic Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 37 Europe Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 38 Europe Locally Advanced Pancreatic Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 39 Europe Locally Advanced Pancreatic Cancer Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 40 Europe Locally Advanced Pancreatic Cancer Market Share, By End-User, 2022 & 2030 (%)

Figure 41 Europe Locally Advanced Pancreatic Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 42 Asia-Pacific Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 43 Asia-Pacific Locally Advanced Pancreatic Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 44 Asia-Pacific Locally Advanced Pancreatic Cancer Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 45 Asia-Pacific Locally Advanced Pancreatic Cancer Market Share, By End-User, 2022 & 2030 (%)

Figure 46 Asia-Pacific Locally Advanced Pancreatic Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 47 Middle East & Africa Locally Advanced Pancreatic Cancer Market Value, 2021-2030 (US$ Billion)

Figure 48 Middle East & Africa Locally Advanced Pancreatic Cancer Market Share, By Therapy, 2022 & 2030 (%)

Figure 49 Middle East & Africa Locally Advanced Pancreatic Cancer Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 50 Middle East & Africa Locally Advanced Pancreatic Cancer Market Share, By End-User, 2022 & 2030 (%)

Figure 51 GSK: Financials

Figure 52 Merck & Co., Inc.: Financials

Figure 53 Bristol-Myers Squibb Company: Financials

Figure 54 Getwell: Financials

Figure 55 Ipsen Biopharmaceuticals, Inc.: Financials

Figure 56 Novartis Pharmaceuticals Corporation: Financials

Figure 57 Pfizer: Financials

Figure 58 Bayer HealthCare Pharmaceuticals, Inc.: Financials

Figure 59 Genentech USA, Inc.: Financials

Figure 60 AstraZeneca: Financials



★調査レポート[局所進行膵がんの世界市場-2024年～2031年] (コード：PH6764)販売に関する免責事項を必ずご確認ください。
★調査レポート[局所進行膵がんの世界市場-2024年～2031年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 細胞・遺伝子治療製造サービスの世界市場レポート（2024年）
  • 標的タンパク質分解市場2020-2030
  • 先進治療薬CDMOの世界市場：現状分析・予測（2022年～2028年）
  • 細胞＆遺伝子治療CDMO市場-規模、シェア、動向分析レポート、予測2024-2030
  • 細胞治療の世界市場
  • 世界のモーター修理＆メンテナンス市場予測2025年-2033年
  • ウイルスベクター製造市場レポート：2030年までの動向、予測、競合分析
  • Global Minimally-Invasive Cosmetic Procedures Market Research Report, By Procedures (Microdermabrasion), Products (Hair Removal Lasers, Botulinum Toxins), Application (Acne & Trauma Scars), And End-Users (Dermatology Clinics) – Global Forecast Till 2027
  • 工業用バーナーの世界市場2024
  • 人工知能(AI)の世界市場2021-2028：市場規模、シェア、動向分析

    • ◆H&Iグローバルリサーチのお客様（例）◆